ANI Pharma executive gets stock grant, withholds shares

ANI Pharmaceuticals executive Thomas Andrew Rowland, SVP and Head of Established Brands, reported equity compensation activity in company common stock.

Rhea-AI Filing Summary

ANI Pharmaceuticals executive Thomas Andrew Rowland, SVP and Head of Established Brands, reported equity compensation activity in company common stock. On February 26, 2026, he acquired 6,021 shares as a restricted stock award at $77.15 per share. This award will vest in four equal annual installments on the first through fourth anniversaries of February 26, 2026.

On February 28, 2026, 628 shares were disposed of at $73.90 per share to cover tax withholding in connection with the vesting of 2,171 previously granted restricted shares. After these transactions, he directly holds 43,502 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Rowland Thomas Andrew

Role SVP, HEAD - ESTABLISHED BRANDS

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	628	$73.90	$46K
Grant/Award	Common Stock	6,021	$77.15	$465K

Holdings After Transaction: Common Stock — 43,502 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.
2. F2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 2,171 shares of restricted stock, the grant of which was previously reported.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ANI Pharmaceuticals (ANIP) report for Thomas Andrew Rowland?

ANI Pharmaceuticals reported that executive Thomas Andrew Rowland received a restricted stock award of 6,021 common shares and had 628 shares withheld to cover taxes relating to vesting of previously granted restricted stock.

How many ANI Pharmaceuticals (ANIP) shares did Thomas Andrew Rowland acquire in this Form 4?

Thomas Andrew Rowland acquired 6,021 shares of ANI Pharmaceuticals common stock as a restricted stock award at $77.15 per share, which represents equity compensation rather than an open‑market purchase or sale of existing holdings.

What is the vesting schedule for the new restricted stock granted to the ANIP executive?

The 6,021 restricted shares granted to the ANI Pharmaceuticals executive will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026, creating a multi‑year retention and incentive structure.

Why were 628 ANI Pharmaceuticals (ANIP) shares disposed of in the Form 4 filing?

The 628 shares were withheld for tax purposes in connection with the vesting of 2,171 restricted shares previously granted, representing a tax‑withholding disposition rather than an open‑market sale of ANI Pharmaceuticals stock by the executive.

How many ANI Pharmaceuticals (ANIP) shares does Thomas Andrew Rowland own after these transactions?

Following the restricted stock award and the tax‑withholding disposition, Thomas Andrew Rowland directly holds 43,502 shares of ANI Pharmaceuticals common stock, reflecting his continuing equity stake as an executive of the company.

Were the ANI Pharmaceuticals (ANIP) insider transactions open‑market buys or sells?

The transactions were not open‑market trades. One entry reflects a restricted stock grant as equity compensation, and the other reflects shares withheld to satisfy tax obligations tied to vesting of previously reported restricted stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rowland Thomas Andrew

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, HEAD - ESTABLISHED BRANDS

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		6,021	A	$77.15	44,130	D
Common Stock	02/28/2026		F(2)		628	D	$73.9	43,502	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 2,171 shares of restricted stock, the grant of which was previously reported.

Remarks:

	/s/ Thomas Rowland, by attorney-in-fact Meredith W. Cook	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.